981P - Pharmacogenomic predictors of cisplatin oto- and nephrotoxicity in head and neck cancer patients treated with chemoradiation

Date 09 October 2016
Event ESMO 2016 Congress
Session Poster display
Topics Head and Neck Cancers
Presenter Eric Winquist
Citation Annals of Oncology (2016) 27 (6): 328-350. 10.1093/annonc/mdw376
Authors E. Winquist1, W.A. Teft2, A. Nichols3, C. Parker3, M. Trinnear1, P. Francis1, N. Bukhari1, J. Lukovic1, Y. Choi2, S. Kuruvilla1, S. Richter1, A. Hammond1, D. Macneil3, N. Read1, K. Fung3, V. Venkatesan1, S. Welch1, D. Palma1, J. Yoo3, R.B. Kim2
  • 1Department Of Oncology, University of Western Ontario, N6A 5W9 - London/CA
  • 2Department Of Medicine, University of Western Ontario, N6A 5A5 - London/CA
  • 3Department Of Otolaryngology-head&neck Surgery, University of Western Ontario, N6A 5W9 - London/CA



Cisplatin-based chemoradiotherapy (CRT) remains a standard treatment for patients (pts) with locally advanced head and neck squamous cell carcinomas (HNSCCs). However, use of cisplatin may cause oto- and nephrotoxicity which may compromise both treatment delivery and longterm quality of life. We hypothesized that polymorphisms (SNPs) in cisplatin methyltransferases (TPMT, COMT), acylphosphatases (ACYP2) and transporters (CTR1, OCT2, MATE1, ABCC2, ABCC3) could predict oto- and nephrotoxicity and investigated this in a prospective cohort study.


Consenting HNSCC pts with adequate baseline hearing and renal function treated with CRT were prospectively enrolled. Audiometric testing was done at baseline, and 3, 6, 12 & 18 months. Serum creatinine was assessed baseline & weekly during CRT. Ototoxicity was defined as ≥grade 2 audiometric change from baseline (CTCAE v4.02) present 12 months post-treatment. Nephrotoxicity was defined as ≥grade 2 acute kidney injury after initiation of cisplatin. Relationships between clinical variables, genotype and outcomes were assessed using Cox regression with interval censoring and reported as a hazard ratio (HR).


207 consecutive HNSCC pts have been enrolled. To date ≥grade 2 ototoxicity has developed in 64% and ≥grade 2 nephrotoxicity observed in 22% of 170 evaluable pts. In multivariate analyses TPMT and COMT SNP carriers were at increased risk of developing ototoxicity (HR 4.47 [95%CI 1.66-12.03, p 


Oto- and nephrotoxicity occur frequently in HNSCC pts treated with CRT. SNPs in both cisplatin metabolizing enzymes and transporters appear to predict vulnerability to these. We plan to assess the clinical utility of these SNPs for toxicity avoidance in a prospective clinical trial.

Clinical trial identification

Not applicable.

Legal entity responsible for the study

University of Western Ontario


Ontario Institute of Cancer Research, Cancer Care Ontario, London Regional Cancer Program, LRCP Medical Oncology Research Fund


All authors have declared no conflicts of interest.